导电系统节奏的前沿:心力衰竭患者长期PR的治疗
Nandita Kaza1, Daniel Keene1, Pugazhendhi Vijayaraman1
1National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.
概括
患有心力衰竭和延长PR间隔的患者面临更高的风险. 导管系统节奏可能比双心脏节奏提供一种更生理的方法来治疗这种情况.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 心脏衰竭管理的管理
背景情况:
- 在心力衰竭患者中,延长PR间隔与不良临床结果有关.
- 潜在的危害包括心室填充量减少和心脏阻塞的进展.
- 孤立PR延长是一个尚未探索的治疗标.
研究的目的:
- 评估导电系统节奏作为心脏衰竭患者与孤立PR延长心室节奏的理想方法.
- 为了探索生理心室节奏比双心室节奏的好处.
主要方法:
- 在心力衰竭中对双心室节拍试验的二次分析.
- 急性血液动力学实验.急性血液动力学实验.
- 他的优化节奏被评估为心力衰竭 (HOPE HF) 随机对照试验.
主要成果:
- 双管节奏推测表明PR延长是预后标志物和治疗目标.
- 导电系统的节奏旨在保持生理心室激活.
- HOPE HF试验证明了生理节奏对心力衰竭症状和左心室功能有好处.
结论:
- 在心力衰竭中,传导系统节奏可能优于双心室节奏,用于隔离PR延长.
- 生理心室节奏表现出改善心力衰竭结果的承诺.
相关概念视频
Conduction System of the Heart
7.6K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
7.6K
Dysrhythmias VI: Management of Dysrhythmias
15
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
15
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Dysrhythmias IV: Characteristics of Bradyarrhythmias
7
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
7
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure Drugs: β-Blockers
344
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
344


